Présentation de l'entreprise
Xencor, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of engineered antibodies designed for the therapeutic treatment of cancer and autoimmune diseases. The company functions within the broader Healthcare sector, specifically specializing in the high-risk, high-reward Biotechnology industry where innovation drives product pipelines rather than established product sales. Its current scale is defined by a market capitalization of $898.40M, an annual revenue of $125.58M, and an organizational structure employing 260 individuals. These valuation and revenue figures indicate that the company maintains a significant market presence for a clinical-stage entity, yet the market cap relative to revenue suggests the valuation is heavily weighted toward the potential of its development pipeline rather than current profitability.
Santé financière
The company reported revenue of $125.58M over the trailing twelve months, accompanied by a net income of $-91,923,000 and an EBITDA of $-166,990,000. The substantial negative gap between the $125.58M revenue and the $-91.9M net income reveals a cost structure characterized by significant operating expenses that exceed total sales, a typical profile for biotechnology firms in clinical development phases. Free cash flow stands at $-39,165,124, indicating that the company is burning cash to fund its research and development efforts, which limits immediate financial flexibility but is necessary for long-term asset creation. All three margins reflect this early-stage financial reality: the gross margin is -90.7%, the operating margin is -189.9%, and the profit margin is -73.2%, each indicating that costs of goods sold and operational overheads currently dwarf the revenue generated. On the balance sheet, Xencor holds $547.73M in cash against $187.75M in debt, resulting in a debt-to-equity ratio of 29.54, which suggests a net cash position where cash assets significantly exceed liabilities despite the high leverage ratio metric. The current ratio of 6.25 demonstrates robust short-term liquidity, implying the company possesses ample current assets to cover its current liabilities many times over. Return on Equity stands at -14.1% and Return on Assets is -12.1%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets due to the lack of profitable operations.
Évaluation de la valorisation
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is reported as -4.10, a discrepancy that implies the market is pricing in future earnings expectations that are not yet realized or are projected to remain negative for the foreseeable future. The price-to-book ratio is 1.39, indicating that the market values the company at a 39% premium over its book value, which often reflects the intangible value of the clinical pipeline and intellectual property rather than physical assets. Alternative valuation metrics show a price-to-sales ratio of 7.15 and an EV/EBITDA of -3.22, suggesting that investors are valuing Xencor based on revenue generation potential and future milestone expectations rather than current profitability or earnings multiples. The stock has traded between a 52-week high of $18.69 and a 52-week low of $6.92, placing the current trading context within a wide range that reflects high volatility typical of biotechnology equities. The beta value is 0.99, indicating that the stock's price volatility moves in tandem with the broader market, offering no significant hedge against or amplification of systemic market risk compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is -46.5%, while earnings growth is N/A due to the absence of positive earnings history. The decline in revenue suggests a contraction in sales or a specific reporting period effect, while the lack of earnings growth data confirms the company is not in a profitable phase where revenue expansion translates directly to net income increases. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is reinvested into research, development, and operational expansion rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage companies that must prioritize capital allocation toward advancing their antibody platforms for cancer and autoimmune indications before they can generate sustainable cash flows. The overall growth and income profile is defined by negative revenue growth and zero dividend income, reflecting a capital-intensive business model focused on future market entry rather than current shareholder returns.